Navigation Links
High Rates of Pathological Complete Response in Patients with Advanced Esophageal Cancer in OPAXIO™ Phase II Study Reported in American Journal of Clinical Oncology
Date:2/23/2011

litaxel. Once inside the tumor cell, enzymes metabolize the protein polymer, releasing the paclitaxel chemotherapy.

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of OPAXIO include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with OPAXIO in particular, including, without limitation, the potential for OPAXIO to be proved safe and effective (or to achieve response rates) for the treatment of the indications noted in this press release or any other indication, determinations by regulatory, patent and administrative governmental authorities, the potential that OPAXIO will not produce high rates of complete remission in patients with advanced esophageal or other cancers, that OPAXIO may not be a selective radiosensitizer, that the data described in this press release may not be validated in a randomized controlled trial, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, and costs of developing, producing and selling OPAXIO. You should also review the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including,
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
4. GlaxoSmithKline Accelerates Review of Exelixis XL880
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
9. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
10. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
11. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... June 2, 2015 Islamic ... mainstream reporting standard for Corporate Sustainability and Social ... big step in CSR: The Islamic Reporting Initiative (IRI). ... last month, the Islamic Reporting Initiative is rapidly ... The latest members to express support for ...
(Date:6/1/2015)... -- LaunchPad Medical, LLC announced today that it has ... Corporation,s (NYSE: SYK ) bone adhesive technology, ... Under the terms of the agreement, LaunchPad has ... this technology which is covered by four issued ... from multiple pre-clinical animal studies.  LaunchPad will seek ...
(Date:6/1/2015)... WOODBRIDGE, ON , June 1, 2015 /PRNewswire/ ... a specialty pharmaceutical company with a focus on ... health, announced its operational highlights and financial results ...  All dollar amounts referenced herein are in Canadian ... to deliver on its business strategies despite its ...
Breaking Medicine Technology:Call for Partners: Islamic CSR 2LaunchPad Medical Executes Definitive License Agreement with Stryker for Novel Bone Adhesive Technology 2Pivotal Therapeutics Announces First Quarter Financial Results 2Pivotal Therapeutics Announces First Quarter Financial Results 3Pivotal Therapeutics Announces First Quarter Financial Results 4Pivotal Therapeutics Announces First Quarter Financial Results 5
(Date:6/2/2015)... Viejo, CA (PRWEB) June 02, 2015 TranSlice: ... with a new style. TranSlice: Reveal allows Final Cut Pro ... and growing lines to reveal their next screen. , TranSlice ... unique style. Final Cut Pro X users can ... and growing lines. , With every panel orientation and direction ...
(Date:6/2/2015)... Amercanex, the American Cannabis Exchange, ... become Amercanex’s new Chief Technology Officer. Amercanex is ... cultivators, wholesale distributors and retail vendors can buy, ... transparent intra-state market. , Jim Miller is an ... space, helping innovative technology companies deliver on their ...
(Date:6/2/2015)... June 02, 2015 Thermi, formerly ... company has successfully transitioned into its new company ... to the company’s continued rapid worldwide expansion and ... of over 25 Thermi employees, including those of ... teams. , “As one of the fastest growing ...
(Date:6/2/2015)... Atlantic Spine Center , a ... three locations in New Jersey, announces the opening of ... facility is at 1045 Park Avenue (at East 86th ... can be arranged by calling 1-844-912-2406. , Dr. ... Center, has been a pioneer in the development of ...
(Date:6/2/2015)... June 02, 2015 Specialty Technical ... compliance and risk solutions , and Radar today ... management effectiveness gap-improvement program. , All organizations need ... on objectives. Organizations not only assess and treat ... to do this (risk managing) thereby embedding these ...
Breaking Medicine News(10 mins):Health News:Announcing the release of TranSlice Reveal from Pixel Film Studios - Professional Split Screen Transitions for FCPX. 2Health News:Amercanex Names Jim Miller to CTO Position 2Health News:Thermi Moves to New Corporate Headquarters as Rapid Company Expansion Continues 2Health News:Renowned Endoscopic Spine Surgeon Dr. Kaixuan Liu Announces Opening of Park Avenue Office 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4
... , Feb. 16 In these difficult times in ... bringing money and services into the Reno area.   ... Start Learning Disabilities Programs Inc. is providing cutting edge educational and ... The $200,000.00 represents a net investment into the area. ...
... University researchers have developed a hands-free alternative to cell phone ... doing it, make it safer," said Juan Gilbert, professor and ... Computing. He said one problem with banning texting while ... He said it will be difficult for police to can,t ...
... radiological evidence suggest broken leg, malaria and genetic disorder ... King Tut probably wasn,t killed by a vengeful wife ... a broken leg and several inherited disorders that rendered ... new DNA and radiological evidence suggests. , "What ...
... Washington, DC Combining tamoxifen, the world,s most prescribed breast ... feverfew may prevent initial or future resistance to the drug, ... reported online in FASEB Feb. 12, provides ... also tests a novel way to get around it. "A ...
... them with a laser has been shown to be a ... occur in places where a laser light can,t reach? Scientists ... directing gold nanoparticles into the nuclei of cancer cells, they ... them where they lurk. The research appeared as a communication ...
... peer-reviewed international journal of the American Cancer Society, ... in its Jan. 1 edition, demonstrating disparities in ... white women. The HealthCore study reiterates ... populations using government health programs that African-American ...
Cached Medicine News:Health News:Reno Children With Disabilities Profit From a Little Known but Internationally Recognized Non-Profit Organization as it Quietly Crosses the $200,000.00 Mark in Service Investment Into the Reno Area 2Health News:King Tut's Demise Gets New Explanation 2Health News:King Tut's Demise Gets New Explanation 3Health News:GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen 2Health News:GUMC researchers say flower power may reduce resistance to breast cancer drug tamoxifen 3Health News:Using gold nanoparticles to hit cancer where it hurts 2Health News:Cancer publishes study confirming disparity in breast cancer treatment 2
For reconstruction, trauma and chronic stenosis of canalicular system. Medical grade silicone tubing (tapered at one end). Blue polypropylene suture. Box of 3, sterile....
Recommended to insert plug portion of all monocanalicular intubation systems into punctum....
For proper plug sizing....
For proper plug sizing....
Medicine Products: